A vitamina D (VD) pode estar envolvida no controle da proliferação, diferenciação e apoptose em linhagens mamárias. Existem evidências de que mulheres com câncer de mama apresentam menor concentração sérica de 25(OH)D3 ou de 1,25(OH)2D3 em relação às mulheres sem câncer. Por outro lado, pouco se sabe se a concentração sérica de VD pode influenciar o desenvolvimento de câncer de mama em cadelas e se o hormônio pode ter efeito quimiopreventivo, inibindo o aparecimento de tumores ou mesmo efeito terapêutico, reduzindo a proliferação de células malignas. Logo, nossos objetivos foram comparar a concentração sérica de 25(OH)D3 em animais com e sem tumor mamário e analisar as ações de 1,25(OH)2D3 em glândulas mamárias normais e tumorais de cadelas, utilizando como modelo a cultura de tecidos. Inicialmente foram incluídas 39 cadelas portadoras de tumor de mama e 64 cães sem tumor (controle), sendo que 50 eram fêmeas e 14 eram machos. Observamos que os animais do grupo tumoral possuíam idade mais avançada (mediana de 108 meses) em relação ao grupo controle (mediana de 36 meses para os machos e 24 meses para as fêmeas). No grupo controle, a concentração sérica foi maior nos machos (32,5 ± 19,3 ng/mL) do que nas fêmeas (22,8 ± 9,6 ng/mL), mas não houve diferença em relação ao grupo tumor (26,62 ± 14,25 ng/mL). Em relação à dieta, a concentração sérica de 25(OH)D3 foi maior nas fêmeas do grupo controle que se alimentavam de ração em comparação às que se alimentavam de comida caseira e ração. Entretanto, não houve diferença em relação à exposição ao sol e características da pelagem em todos os animais. No grupo tumoral, houve correlação inversa da concentração sérica de 25(OH)D3 em relação à idade, mas não houve diferença quanto ao tipo histológico ou estadiamento da doença. Foram coletadas 70 amostras de tumor de mama e de tecido mamários normal de cadelas, as quais foram cultivadas em fatias. Dos tecidos tumorais, 50% eram positivos para receptor de estrógeno (acima de 10% de células marcadas) e 44% eram positivos para HER-2 (método HercepTest). Detectou-se expressão gênica e proteica do receptor da vitamina D (VDR) em tecido mamário normal e tumoral, sendo identificado três padrões na imunoistoquímica: I - células epiteliais e mioepiteliais (mais frequentemente encontrada em tecido normal), II - marcação predominante em células mioepiteliais (mais comum em tecido tumoral e III - marcação predominante em células epiteliais. As amostras foram tratadas com 1,25(OH)2D3 nas concentrações 0,228 nM, 2 nM e 100 nM (concentração fisiológica, farmacológica que não induz hipercalcemia e farmacológica que induz hipercalcemia, respectivamente). O conteúdo de VD tecidual avaliado por cromatografia líquida foi crescente de acordo com as concentrações de VD utilizadas, indicando penetração do hormônio nas fatias. Observou-se indução da expressão de CYP24A1, que variou de 27 a 158 vezes dependendo da concentração utilizada, indicando ativação genômica da via da VD e que o tecido permanece metabolicamente ativo em cultura. Entretanto, não houve diferença da expressão gênica de outros genes envolvidos com o metabolismo da VD (CYP27B1), genes envolvidos no controle da proliferação (CDKN1A e CDKN1B) e genes envolvidos com a imunidade (CD14). O tratamento com calcitriol nas diferentes concentrações não induziu a apoptose (expressão proteica de caspase-3 clivada) e não alterou a proliferação nos tecidos normais (expressão proteica de Ki-67), mas diminuiu a proliferação nos tecidos tumorais. Não foi observada correlação entre a indução da apoptose e redução da proliferação com os padrões de expressão proteica de VDR. Concluindo, não observamos diferença na concentração sérica de 25(OH)D3 entre cadelas com tumor de mama e animais controle. Detectamos que o calcitriol em concentração fisiológica ativa a via genômica de VD em mama normal e tumoral e reduz o índice de proliferação (expressão de Ki-67) nos tumores de mama / Vitamin D (VD) may be involved in the control of proliferation, differentiation and apoptosis of mammary cell lines exposed to high concentrations of the hormone. There is some evidence that women with breast cancer present lower serum level of 25(OH)D3 or 1,25(OH)2D3 compared to women without cancer. Moreover, little is known if serum concentration of VD can influence the development of mammary tumors in dogs and if the hormone may have chemopreventive effect by inhibiting the appearance of tumors or therapeutic effect, reducing the proliferation of malignant cells. Therefore, our goals were to compare the serum 25(OH)D3 level in animals with and without mammary tumor and to analyze 1,25(OH)2D3 effects in normal and tumoral canine mammary glands, using as a model the tissue culture. At first, 39 bitches with mammary tumor and 64 dogs without tumor (control), of which 50 were females and 14 were males were included. Animals in tumor group were older (median 108 months) compared to control group (median 36 months for males and 24 months for females). In control group, serum concentration was higher in males (32.5 ± 19.3 ng/mL) than in females (22.8 ± 9.6 ng/mL), but there was no difference when compared to tumor group (26.62 ± 14.25 ng/mL). Regarding diet, serum 25(OH)D3 level was higher in control bitches fed commercial pet food compared to those fed homemade and commercial pet food combined. However, there was no difference of serum 25(OH)D3 concentration, sun exposure and coat features. In tumor group, there was an inverse correlation between serum 25(OH)D3 and age, but there was no difference in 25(OH)D3 concentration among bitches with different histological type or clinical stage of the disease. Seventhy bitches diagnosed with mammary tumors had tumor and mammary samples collected, sliced and cultured. In tumor tissues, 50% were positive for estrogen receptor (over 10% of cells stained), and 44% were positive for HER-2 (HercepTest method). Vitamin D receptor (VDR) protein and genic expression was detected in normal and tumoral samples. Three patterns of VDR were detected by immunohistochemistry: I - localizated in epithelial and myoepithelial cells (more often in normal tissues), II - predominantly in myoepithelial cells (most common in tumor tissues) and III - predominantly in epithelial cells. Normal anmammary slices were treated with 1,25(OH)2D3 0.228 and 100nM concentrations (concentration physiological and pharmacological, respectively) and mammay tumor slices were treated with 1,25(OH)2D3 2 nM concentrations (drug concentration which does not induce hypercalcemia) and 100 nM, for 24 hours. VD tissue content measured by liquid chromatography was higher in samples exposed to high VD concentration, indicating penetration of the hormone in slices. VD treatment induced CYP24A1 expression, 27 to 158 fold depending on the concentration used, and indicating activation of the VD genomic pathway. This result also suggest that the tissue remains metabolically active in culture. However, no difference in gene expression of other target genes such as CYP27B1, genes involved in proliferation as CDKN1A and CDKN1B and genes involved in immunity, such as CD14. Calcitriol treatment at different concentrations did not induce apoptosis (protein expression of cleaved caspase-3) and did not alter proliferation in normal tissues (expression of protein Ki -67), but decreased proliferation in tumor tissues. No correlation was observed between the induction of apoptosis and reduction of proliferation with the protein expression patterns of VDR. In conclusion, no difference in serum 25(OH)D3 between bitches with mammary tumor and control animals was observed. In normal and tumoral mammary samples calcitriol physiologic concentration activated VD genomic pathway and in tumor samples calcitriol reduced the proliferation index (Ki-67)

Abstract Pulmonary fibrosis, lung cancer and chronic obstructive pulmonary disease (COPD) are severe diseases and common death causes worldwide. Due to the lack of an effective therapy, the investigation of cell biological mechanisms behind these diseases is essential. An activation of stromal cells, including myofibroblasts, is a main feature found in the pathogenesis of lung diseases. Myofibroblasts express alpha-smooth muscle actin (α-SMA), have specific ultrastructure, produce extracellular matrix proteins and possess contractile capacity. Detailed structure and function of myofibroblasts and their roles in healthy and diseased lung are not yet wholly understood. The investigation of the myofibroblasts may further offer novel tools for the acquisition of proper diagnosis, prognosis and medical treatment. The study aimed to characterize the ultrastructural, functional and disease-specific features of stromal cells, particularly myofibroblasts, in interstitial and malignant lung diseases. The functional properties evaluated here were differentiation, invasive and contractile properties. The study material included in vitro stromal cells cultured from bronchoalveolar lavage (BAL) fluids. The appearance and location of myofibroblasts in different lung compartments of non-smokers and the COPD-patients were examined in vivo. The cells were investigated by light and electron microscopy. The α-SMA expression was analysed by gene or protein assays. The study demonstrated that stromal cells could be cultured from diagnostic BAL fluid samples and lung tissues. Cultured cells were a mixture of fibroblasts and myofibroblasts. A small proportion of cells exhibited progenitor-like features. Myofibroblasts revealed differential features in electron microscopy and invasive or contractile assays. When studying tissues from healthy and COPD lungs, myofibroblasts were located both in alveoli and airways. In alveoli myofibroblasts localized in widened alveolar tips which were newly described structures and locations of myofibroblasts in healthy and diseased lung. The amount of myofibroblasts in large airways, but not in peripheral lung, was increased in COPD. We concluded that myofibroblasts have several locations in normal and COPD lung, which suggests a function both in pulmonary regeneration and the pathogenesis of COPD. Smoking altered the phenotype of myofibroblasts regardless of its origin. / Tiivistelmä Keuhkofibroosi, keuhkosyöpä ja keuhkoahtaumatauti (COPD) ovat kansallisesti ja maailmanlaajuisesti yleisiä ja kuolemaan johtavia sairauksia. Taudinmääritys ja hoito ovat vaativia, eikä kaikille potilaille ole parantavaa hoitoa. Keuhkosairauksien kaikkia solubiologisia mekanismeja ei vielä tunneta, mikä on yksi syy lääkekehityksen ongelmiin. Interstitiaaleissa ja pahanlaatuisissa keuhkosairauksissa esiintyy paljon aktiivisia sidekudossoluja, kuten muuntuneita fibroblasteja eli myofibroblasteja. Ne tunnistetaan hienorakenteesta, jota voidaan tutkia elektronimikroskoopilla. Myofibroblastit ilmentävät myös solun sisäistä sileän lihaksen alfa-aktiinia (α-SMA), tuottavat sidekudoksen proteiineja ja kykenevät supistumaan. Myofibroblastien hienorakenteen ja toiminnan selvittäminen voi antaa lisätietoa keuhkosairauksien syntymekanismeista, jolloin diagnostiikkaa, ennustetta sekä hoitoja voidaan arvioida paremmin. Väitöskirjassa selvitettiin myofibroblastien hienorakennetta ja toimintaa eri keuhkosairauksissa. Tutkitut toiminnalliset ominaisuudet olivat erilaistumispotentiaali, invasiivisuus ja supistumiskyky. Sairauksien kliinistä käyttäytymistä ja potilaiden tupakointitottumuksia tarkasteltiin suhteessa solubiologiatason havaintoihin. Tutkimusmateriaali kerättiin taudinmäärityksen yhteydessä interstitiaalisia keuhkosairauksia, keuhkoahtaumatautia tai keuhkosyöpää sairastavilta potilailta. Tulosten mukaan bronkoalveolaarihuuhtelunesteestä (BAL) ja keuhkokudospaloista voidaan soluviljelymenetelmin kasvattaa ja ylläpitää solulinjoja. Viljellyt solut muodostivat sekasolupopulaatiota, joissa esiintyi pääosin fibroblasteja ja vaihteleva osuus myofibroblasteja. Pieni osa soluista ilmensi kantasoluille tyypillisiä piirteitä. Myofibroblastien tyyppipiirteet ja toiminnalliset ominaisuudet vaihtelivat taudeittain. Kudoksessa myofibroblasteja ilmentyi sekä keuhkorakkuloissa että ilmateissä. Keuhkorakkulatasolla myofibroblastit sijoittuivat irrallisten alveoliseinämien laajentuneisiin päihin, joita ei ole aiemmin tutkittu tieteellisessä kirjallisuudessa myofibroblastien yhteydessä. Keuhkoahtaumatauti ja tupakointi vähensivät näiden rakenteiden määrää perifeerisessä keuhkossa, kun taas suurissa ilmateissä keuhkoahtaumatauti lisäsi myofibroblasteja. Päättelimme, että myofibroblastit edistävät keuhkoahtaumataudin syntyä isoissa ilmateissä, mutta saattavat osallistua keuhkojen korjaukseen keuhkorakkuloissa ja pienissä ilmateissä.

Topographical and mechanical properties of adhesive substrates provide important biological cues that affect cell spreading, migration, growth, and differentiation. The phenomenon has led to the increased use of topographically patterned and flexible substrates in studying cultured cells. However, these studies may be complicated by various limitations. For example, the effects of ligand distribution and porosity are affected by topographical features of 3D biological constructs. Similarly, many studies of mechanical cues are compounded with cellular deformation from external forces, or limited by comparative studies of separate cells on different substrates. Furthermore, understanding cell responses to mechanical input is dependent upon reliable measurements of mechanical properties. This work addresses each of these issues. To determine how substrate topography and focal adhesion kinase (FAK) affect cell shape and movement, I studied FAK-null (FAK -/-) and wild type mouse 3T3 fibroblasts on chemically identical polystyrene substrates with either flat surfaces or micron-sized pillars, I found that, compared to cells on flat surfaces, those on pillar substrates showed a more branched shape, an increased linear speed, and a decreased directional stability, which were dependent on both myosin-II and FAK. To study the dynamic responses to changes in substrate stiffness without other confounding effects, I developed a UV-modulatable substrate that softens upon UV irradiation. As atomic force microscopy (AFM) proved inadequate to detect microscale changes in stiffness, I first developed and validated a microsphere indentation method that is compatible with fluorescence microscopy. The results obtained with this method were comparable to those obtained with AFM. The UV-modulatable substrates softened by ~20-30% with an intensity of irradiation that has no detectable effect on 3T3 cells on control surfaces. Cells responded to global softening of the substrate with an initial retraction followed by a gradual reduction in spread area. Precise spatial control of softening is also possible - while there was little response to posterior softening, anterior softening elicited a pronounced retraction and either a reversal of cell polarity or a significant decrease in spread area if the cells move into the softened region. In conclusion, these techniques provide advances in gaining mechanistic insight into cellular responses to topographical and mechanical cues. Additionally, there are various other potential applications of the novel UV-softening substrate, particularly in regenerative medicine and tissue engineering.

No / Phosphorylation or SUMOylation of the kainate receptor (KAR) subunit GluK2 have both individually been shown to regulate KAR surface expression. However, it is unknown whether phosphorylation and SUMOylation of GluK2 are important for activity-dependent KAR synaptic plasticity. We found that protein kinase C-mediated phosphorylation of GluK2 at serine 868 promotes GluK2 SUMOylation at lysine 886 and that both of these events are necessary for the internalization of GluK2-containing KARs that occurs during long-term depression of KAR-mediated synaptic transmission at rat hippocampal mossy fiber synapses. Conversely, phosphorylation of GluK2 at serine 868 in the absence of SUMOylation led to an increase in KAR surface expression by facilitating receptor recycling between endosomal compartments and the plasma membrane. Our results suggest a role for the dynamic control of synaptic SUMOylation in the regulation of KAR synaptic transmission and plasticity.

No / Hair disorders cause psychological distress but are generally poorly controlled; more effective treatments are required. Despite the long-standing use of minoxidil for balding, its mechanism is unclear; suggestions include action on vasculature or follicle cells. Similar drugs also stimulate hair, implicating ATP-sensitive potassium (K(ATP)) channels. To investigate whether K(ATP) channels are present in human follicles, we used organ culture, molecular biological, and immunohistological approaches. Minoxidil and tolbutamide, a K(ATP) channel blocker, opposed each other's effects on the growing phase (anagen) of scalp follicles cultured in media with and without insulin. Reverse transcriptase-polymerase chain reaction identified K(ATP) channel component gene expression including regulatory sulfonylurea receptors (SUR) SUR1 and SUR2B but not SUR2A and pore-forming subunits (Kir) Kir6.1 and Kir6.2. When hair bulb tissues were examined separately, epithelial matrix expressed SUR1 and Kir6.2, whereas both dermal papilla and sheath exhibited SUR2B and Kir6.1. Immunohistochemistry demonstrated similar protein distributions. Thus, human follicles respond biologically to K(ATP) channel regulators in culture and express genes and proteins for two K(ATP) channels, Kir6.2/SUR1 and Kir6.1/SUR2B; minoxidil only stimulates SUR2 channels. These findings indicate that human follicular dermal papillae contain K(ATP) channels that can respond to minoxidil and that tolbutamide may suppress hair growth clinically; novel drugs designed specifically for these channels could treat hair disorders.

Dissertation (Ph.D.)--University of South Florida, 2009. / Title from PDF of title page. Document formatted into pages; contains 164 pages. Includes vita. Includes bibliographical references.

Balding causes widespread psychological distress but is poorly controlled. The commonest treatment, minoxidil, was originally an antihypertensive drug that promoted unwanted hair. We hypothesized that another serendipitous discovery, increased eyelash growth side-effects of prostamide F(2alpha)-related eyedrops for glaucoma, may be relevant for scalp alopecias. Eyelash hairs and follicles are highly specialized and remain unaffected by androgens that inhibit scalp follicles and stimulate many others. Therefore, we investigated whether non-eyelash follicles could respond to bimatoprost, a prostamide F(2alpha) analog recently licensed for eyelash hypotrichosis. Bimatoprost, at pharmacologically selective concentrations, increased hair synthesis in scalp follicle organ culture and advanced mouse pelage hair regrowth in vivo compared to vehicle alone. A prostamide receptor antagonist blocked isolated follicle growth, confirming a direct, receptor-mediated mechanism within follicles; RT-PCR analysis identified 3 relevant receptor genes in scalp follicles in vivo. Receptors were located in the key follicle regulator, the dermal papilla, by analyzing individual follicular structures and immunohistochemistry. Thus, bimatoprost stimulates human scalp follicles in culture and rodent pelage follicles in vivo, mirroring eyelash behavior, and scalp follicles contain bimatoprost-sensitive prostamide receptors in vivo. This highlights a new follicular signaling system and confirms that bimatoprost offers a novel, low-risk therapeutic approach for scalp alopecias.